"Nebilong": ntuziaka maka ojiji. "Nebilong": reviews na analogues

"Nebilong" bụ irè ọgwụ maka ọgwụgwọ nke ọrịa metụtara na mkpọchị n'obi ọrụ. Mmeli mma na-eme mgbe na-eji ya maka otu ọnwa. Mgbe ngwa "Nebilonga" normalized usu na ọbara mgbali, vaskụla ntụrụndụ na-ruru, ndị myocardium na-ọnọ zuru ezu oxygen. Na fọrọ nke nta niile ikpe a mma n'ihi nke ọgwụ na-edebe ruo ogologo oge.

Mejupụtara, mejupụtara

The na nkà mmụta ọgwụ dị na mbadamba. Onye ọ bụla mbadamba nwere ike ibu 2.5, 5 ma ọ bụ 10 mg nke nọ n'ọrụ mgwa. The na nkà mmụta ọgwụ na-mere na ndabere nke nebivolol hydrochloride. Nke excipients ugbu ke mejupụtara nke povidone, lactose, magnesium stearate. Mejupụtara gbakwunyere na talc, microcrystalline cellulose, sodium dioctyl sulfate, colloidal sịlịkọn dioxide, croscarmellose sodium, Beta-cyclodextrin.

pharmacological mmetụta

"Nebilong" ntụziaka ntuziaka ngosipụta dị ka a pụtara na-enwe na ya Ọdịdị abụọ enantiomers (L- na D-nebivolol). D-nebivolol - ukwuu nhọrọ, asọmpi β1-adrenoceptor blocker, L-nebivolol nwayọọ na ọbara arịa, kọwakwuru ha, nke bụ n'ihi na a usoro na vaskụla endothelium (ntọhapụ vasodilating mgbanwe olu na-akpata).

Nebivolol ebelata ọbara mgbali na obi ọnụego, n'ihi bụ echekwara bụghị nanị na quiescent obodo kamakwa n'okpuru ibu. Mgbe na-ewere ọgwụ na gburugburu na end-diastolic ekpe ventricular nrụgide na-ebelata, e nwere nti mmetụta na otu nke ọrụ rụrụ site n'obi - diastolic. N'ihi na ngwa nke "Nebilonga" ejection nta na-abawanye, ndị mmadụ na IBS akara antianginal mmetụta.

Hypotensive mee ihe e mere mbadamba "Nebilong" ndu na-akọwa na ojuju na-arụ ọrụ na renin-angiotensin usoro. Antiarrhythmic edinam na-enweta site na mbenata na AV-conduction na n'igbochi ndiiche automaticity obi. Kwagidere hypotensive mmetụta emee n'ime 7-14 ụbọchị nke ọgwụgwọ, mgbe - na a ọnwa. Anụ n'ihi na-ewere mbadamba hụrụ mgbe otu ọnwa abụọ nke ọgwụgwọ.

Pharmacokinetics

The ọgwụ ingested, etinye obi gị dum ọma, usoro dokwara irè n'agbanyeghị nke nri. Metabolism na imeju na-na enwezu guzobe nke nọ n'ọrụ gidroksimetabolitov. The nkezi bioavailability mgbe ngwa nke esịtidem agwọ ọrịa onye a ngwa ngwa metabolism nke 12%, nke a ọnụ ọgụgụ nnọọ elu karịa na-adịghị ngwa metabolism. Ebe ọ bụ na metabolism nke ọrịa nwere ike ime n'ọtụtụ dịgasị iche iche, "Nebilong" ntuziaka na-atụ aro maka ojiji na onye e ji mara onye ọrịa ahụ. Na a ngwa ngwa metabolism na-eji ala doses nke ọgwụ. Na-achị na ngwa ngwa mgbanwe nke bekee na-ewe ebe ọkara ndụ nke ihe dị ka awa 10, na ọrịa ndị na-nwere a ngwa ngwa metabolism, ọkara ndụ mụbara site 3-5 ugboro. Mgbe ụbọchị asaa nke ọrịa, banyere 38% natara ọgwụ anyụpụ site akụrụ, banyere 48% "Nebilonga" bụ ugbu ke stool. The mejupụtara nke mmamịrị bụ a obere ego nke ọgwụ na-agbanweghi agbanwe - ruo 0,5%.

na-agba akaebe

Na ngwa nke "Nebilong" ntụziaka nwere ike ji mee ihe maka ọbara mgbali elu, maka mmejuputa iwu mgbochi na ọrịa na CAD (oké nke rịaworo) na maka mmejuputa iwu nke mgbagwoju ọgwụ nke obi ọdịda nke-adịghị ala ala ụdị.

Ọgwụgwọ na ọgwụ "Nebilong"

ọbara mgbali

Okenye ọrịa ndinọ 5 mg "Nebilonga", nke kwekọrọ na a mbadamba Nwa bụ kwa ụbọchị dose. The na nkà mmụta ọgwụ na-atụ aro iji kwa ụbọchị n'otu oge. A obere mmetụta dị kwesiri ngosi mgbe otu izu abụọ nke ọgwụ, ndị kasị akpọ, ọ bụ a ọnwa n'oge nke ọgwụgwọ a rụrụ. Mbadamba adabara mmejuputa monotherapy na maka ọgwụgwọ nke dabeere na integrated iji ọgwụ ọjọọ eme, nke nwekwara hypotensive mmetụta. Ndị mmadụ na-iri "Nebilong AM", ntụziaka na-atụ aro iji nweta ihe ọzọ mmetụta itinye "Hydrochlorothiazide" nke 12.5-25 mg. Dị otú ahụ jikọtara omume ike welie ihe nke "Nebilonga", ma ọ ga-mere naanị mgbe na-anata ndụmọdụ nke ịga dibịa.

Heart ọdịda a-adịghị ala ala ụdị

First a obere dose of agwọ ọrịa, ndị dibịa nwayọọ nwayọọ na-abawanye, nyere àgwà nke ndidi. Maka ọgwụgwọ nke nnukwu iche nke "Nebilong" bụghị ihe kwesịrị ekwesị, dị otú ahụ ikpe, ndị ọzọ ọgwụ ọjọọ eme ihe e ji. Abụkarị ụzọ kenyere ka 1.25 mg nke ọgwụ n'ihi na ozugbo ihe kwa ụbọchị na, mgbe 1-2 izu na dose nwere ike mụbara 5 mg, na mgbe e mesịrị - ruo 10 mg. The kwa ụbọchị dose ekwesịghị gafere 10 mg agwọ ọrịa "Nebilong". Ntuziaka maka ojiji na-egosi na na mbụ ogbo nke ọgwụ ọrịa na-ekpe n'okpuru chọpụtara maka awa abụọ mgbe ingestion nke mbadamba, otú onye ọ bụla na-amụba dose n'aka. Mụbara dose nwere ike belata ọzọ ma ọ bụrụ na ọ dị mkpa dị.

Ọ bụrụ na obi odida mgbaàmà pụtara ọzọ akpọ ma ọ bụ na-enwe ndidi ekweghị ibe nọrọ ọgwụ mmiri chọtara, belata dose nke ọgwụ ma ọ bụ na-emepụta ya ekpochapụ. A, obi ọdịda, adịghị ala ala ụdị "Nebilongom" emeso ngwa ngwa. Mgbe ọgwụ iji na-ewepụ ndị dị otú ahụ ọnọdụ,-ekpochapụ nke ọgwụ na-eji nwayọọ nwayọọ, ị nwere ike adịghị eme nke a sharply, n'ihi na nsogbu ahụ nwere ike enwe nnukwu. Ọ bụrụ na ị kagburu ọgwụ kwa izu ike ibelata dose ọkara. N'ihi na-ewere mkpụrụ ọgwụ "Nebilong AM" ntụziaka ntuziaka na-enye maka mgbochi ụfọdụ.

mgbochi:

• Gbasara akụrụ insufficiency. Akpa, maka ọgwụ iji 2,5 mg nke ọgwụ kwa ụbọchị, na-dose nwere ike mụbara e mesịrị, ma ọ ekwesịghị gafere 5 mg.
• Older afọ. The mbụ dose nwere ike gafere 2,5 mg ma ọ bụrụ na ọ dị mkpa, a na-akpọlite 5 mg. Mgbe afọ 65, na-achọ mgbe nile nnyocha akụrụ (onye ọ bụla anọ ise ọnwa).
• Pregnancy. A mụrụ nwa ọhụrụ nwere ike ịzụlite ọrịa ụfọdụ, ndị a na-agụnye akụkụ okuku ume na mkpọnwụ, hypoglycemia, hypotension, bradycardia, otú ụmụ nwaanyị dị ime na ọgwụ a na-kenyere nnọọ adịkarịghị. Ọ bụrụ na nwaanyị dị ime na-eji "Nebilong" ya kagbuo a chọrọ maka 48-72 awa tupu nnyefe. Ọ bụrụ na nke a agaghị ekwe omume, a mụrụ nwa ọhụrụ ga-hụrụ maka 48-72 awa.

contraindications

"Nebilong H" ntụziaka ntuziaka machibidoro ojiji na ndị na-esonụ mgbe:

• nká na-erughị afọ 18;
• hypersensitivity ọgwụ mmiri;
• bronchospasm, ụkwara ume ọkụ (akụkọ ihe mere eme);
• pheochromocytoma, nke bụghị e mesoro n'ihu;
• metabolic acidosis;
• ike na-ewere ọnọdụ ọrịa imeju, imeju ọdịda;
• hypotension na ndị mmadụ n'otu n'otu onye systolic mgbali nke 90 mm HG ma ọ bụ obere. Nkeji edemede.;
• AV-ngọngọ (ọkwa m, III), bradycardia, nke na-esonyere obi ọnụego kwekọrọ 60 bpm. kwa nkeji;
• n'oge n'ịmụ nwa, ara;
• nnukwu obi odida udi;
• nsogbu na elu mgbasa, na doro anya expressiveness;
• cardiogenic ujo, a ọnọdụ nke na ọ dị mkpa iji isotropic ọgwụ ọjọọ;
• syndrome, na-arịa ọrịa imi so.

ịkpachara anya a chọrọ mgbe n'ịhọpụta ọgwụ ọrịa na ọnọdụ:

• arịa ọrịa shuga;
• psoriasis (akụkọ ihe mere eme);
• Prinzmetal rịaworo.

mmetụta

Na ọgwụgwọ pụtara "Nebilong" ntụziaka ntuziaka, reviews asị gbasara nke puru omume na omume ụfọdụ mmetụta, nke na-egosipụta na-arụ ọrụ nke obi, digestive na ụjọ usoro. Tinyere ihe ndị ọzọ imebi - bronchoconstriction mmeghachi omume na-emetụta ndị akpụkpọ ọnọdụ.

adọ aka ná ntị

"Nebilong" nwere ike ike uche na allergens, nke egwu mmepe nke oké anaphylactic mmeghachi omume.

Drug ọgwụgwọ adịghị emetụta larịị nke glucose ke idem na ọnụnọ nke-arịa ọrịa shuga, ma ọrịa na otu a nwere itinye ọgwụ na ịkpachara anya. Dị ka ọrịa shuga na na hyperthyroidism ọgwụ pụrụ ikpuchi ihe mgbaàmà nke tachycardia, ọ bụ ndị ọzọ akpọ n'ihi na mberede ndọrọ ego nke mbadamba.

Ọ bụrụ na ọrịa na nsogbu na akụkụ okuku ume na usoro a na-eji "Nebilong" ntụziaka ntuziaka na-agwa banyere puru nke uru constriction nke karị na COPD. Ekwe omume nke na ijikọta ọgwụ na ọgwụ ọjọọ ndị ọzọ ga-enyocha na dọkịta gị.

"Nebilong" na-emetụta ikike ụgbọala na ụgbọala, nwere ike ime ka ike ọgwụgwụ na dizziness.

analogs

Ọ bụ omume na-eji dochie ọgwụ na-adịghị ekwe ka ojiji nke ọgwụ ọjọọ, "Nebilong" ntụziaka ntuziaka. Drug analogues agụnye "Nebilet", "Binelol". Site nọ n'ọnọdụ na-agụnye "Nebikor" na "Nebivator".

Nyocha

Dị ka reviews, ọgwụ dị irè mgbe eji n'ụzọ ziri ezi. Ọ dị mkpa na-eji ọgwụ na-eso niile dọkịta na-atụ aro. The agwọ ọrịa na-kenyere na contraindications na e ji mara onye ọrịa, na-akpata a mmetụta dị mma. Na ọgwụgwọ na-eduga mmepe nke mmetụta, mkpa ka i mgbe niile nyochaa ọnọdụ nke onye ọrịa.